Journal List > J Korean Med Assoc > v.49(10) > 1080697

Jo: Deficiency Anemia

Abstract

Iron deficiency anemia (IDA) and megaloblastic anemia due to vitamin B12 deficiency are well-characterized prototypes of anemia. There is no doubt that IDA is the most common hematologic disorder in Korea and worldwide as well. The diagnosis and treatment of IDA is not a difficult practice usually, however, a caution is required in detecting early-stage iron deficiency and in distinguishing IDA from anemia of chronic disorders such as chronic inflammatory disease, malignancies, chronic liver disease, and chronic renal disease. Administration of a standard iron preparation at a proper dosage over an adequate period is a prerequisite for the successful treatment of IDA, which is sometimes overlooked by both physicians and patients. Early detection and treatment as well as prevention of iron deficiency per se are also required. Pernicious anemia is the most common cause of vitamin B12 deficiency in Western populations. By contrast, the disorder is rare in Korea, although the number of cases seems to be increasing these days. The majority of patients with megaloblastic anemia reveal a history of gastrectomy. Thus, it should be reminded that vitamin B12 supplementation is important to prevent the development of overt deficiency or anemia in these susceptible individuals, since a delay in the treatment of vitamin B12 deficiency may result in an irreversible neurologic deficit.

Figures and Tables

Table 1
Etiology of iron deficiency anemia
jkma-49-874-i001

References

1. Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal J, editors. Williams Hematology. 2006. 7th ed. New York: McGraw-Hill Medical;511–553.
3. Cook JD. Newer aspects of the diagnosis and treatment of iron deficiency. Hematology. 2003. 53–57.
4. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002. 48:1066–1076.
crossref
5. Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin. A metablolite with a mission. Clin Chem. 1999. 45:2060–2072.
6. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood. 1990. 75:102–107.
crossref
7. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003. 329:9–22.
crossref
8. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood. 1990. 75:1870–1876.
crossref
9. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003. 101:3359–3363.
crossref
10. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, et al. Diagnosis of iron deficiency anemia in the elderly. Am J Med. 1990. 88:205–209.
11. Guyatt GH, Oxman AD, Ali M, Willan A, Mcilory W, Patterson C. Laboratory diagnosis of iron deficiency anemia; an overview. J Gen Intern Med. 1992. 7:145–153.
12. Intragumtornchai T, Ronjukkarin P, Swaskikul D, Israsena S. The role of serum ferritin in the diagnosis of iron deficiency anaemia in patients with liver cirrhosis. J Intern Med. 1998. 243:233–241.
crossref
13. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992. 119:385–590.
14. Fishbane S. Intravenous iron therapy: reweighing risk and reward. Semin Dialysis. 1999. 12:5–8.
crossref
15. Drueke TB, Barany P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol. 1997. 48:1–8.
16. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999. 10:2029–2043.
17. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997. 337:1441–1448.
crossref
18. Chun JM, Park NS, Park NH, Yun GW, Yang YJ, Park SE, et al. Pernicous anemia. A retrospective analysis of 22 cases. Korean J Hematol. 2005. 40:219–225.
crossref
19. Song HH, Kwon JH, Kim JH, Jeong JY, Kim HJ, Lee KS, et al. Causes and clinical features of vitamine B12 deficiency megaloblastic anemia. Korean J Hematol. 2004. 39:243–248.
20. Andres E, Loukili NH, Noel E, Kaltenbach G, Abelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004. 171:251–259.
crossref
21. Andres E, Perrin AE, Demangeat C, Kertz JE, Vinzio S, Grunenberger F, et al. The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine. A monocentric cohort study of 80 patients. Eur J Intern Med. 2003. 14:221–226.
crossref
22. Toh BH, Alderuccio F. Pernicious anemia. Autoimmunity. 2004. 37:357–361.
23. Perez-Perez GI. Role of Helicobacter pylori infection in the development of pernicious anemia. Clin Infect Dis. 1997. 25:1020–1022.
crossref
24. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer. 1993. 71:745–750.
crossref
25. Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993. 34:28–32.
crossref
26. Carmel R. Reassessment of the relative prevalence of antibodies to gastric parietal cell and to intrinsic factor in patients with pernicious anaemia: influence of patient age and race. Clin Exp Immunol. 1992. 89:74–77.
crossref
27. Doscherholmen A, Hagen PS, Liu M, Olin L. A dual mechanism of vitamin B12 plasma absorption. J Clin Invest. 1957. 36:1551–1557.
28. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998. 92:1191–1198.
crossref
29. Park MR, Shim H. Oral mecobalamin treatment in cobalamin deficiency. Korean J Hematol. 2004. 39:228–232.
TOOLS
Similar articles